Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory

We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.'s share was trading at $12.48 as of February 18th.

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. NTLA represents a potentially transformative opportunity in the biotechnology space, anchored by its pioneering work in in-vivo CRISPR gene editing. The company is among the first to demonstrate...